Feroze U.
About Feroze U.
Feroze U. serves as the Chief Business Officer at Terray Therapeutics, where he oversees business development and pipeline strategy. He has a strong background in chemistry, holding a BSc and PhD from Imperial College London and a post-doctorate from The University of Texas at Austin, along with extensive experience in drug discovery and business development at Merck.
Current Role at Terray Therapeutics
Feroze U. serves as the Chief Business Officer at Terray Therapeutics, a position he has held since 2023. In this role, he is responsible for the company's business development and pipeline strategy. His leadership focuses on advancing the company's initiatives in therapeutic discovery and development. Prior to this role, he was the Head of Business at Terray Therapeutics from 2022 to 2023, contributing to the company's strategic direction during a pivotal time.
Previous Experience at Merck
Feroze U. has extensive experience in the pharmaceutical industry, particularly during his tenure at Merck & Co., Inc. He joined Merck in 1995 as a Senior Research Chemist and progressed to the position of Executive Director of Chemistry. He also served as Director of Business Development and Licensing, where he executed licensing deals and formed strategic partnerships involving advanced technologies such as DNA-Encoded Library Technology and mRNA Display Technology. His leadership in discovery programs resulted in eight preclinical development candidates, with three advancing to clinical trials.
Educational Background
Feroze U. completed his undergraduate studies at Imperial College London, earning a Bachelor of Science in Chemistry from 1987 to 1990. He continued at the same institution to obtain a PhD in Organic Chemistry from 1990 to 1993. Following his doctoral studies, he pursued a Post-Doctorate in Organic Chemistry at The University of Texas at Austin from 1993 to 1995. This strong educational foundation in chemistry has supported his career in both research and business development within the pharmaceutical sector.
Research Contributions and Publications
Feroze U. has made significant contributions to the field of chemistry and pharmaceuticals, authoring over 85 publications and patents throughout his career. His research includes the discovery of the first-in-class small molecule MC4R agonist, MK-0493, aimed at obesity treatment. His work has played a crucial role in advancing therapeutic options and enhancing understanding in the field.